NTHI NEONC TECHNOLOGIES HOLDINGS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1979414 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.0%
TTM EPS YoY25.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-642.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets241.6%
Debt / equity—
Current ratio0.38x
Interest coverage-15.69x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-337.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $39,990 | $83,000 |
| R&D expense | $3.64M | $3.05M |
| SG&A expense | $4.82M | $1.68M |
| Operating income | -$58.24M | -$7.14M |
| Interest expense | $2.50M | $2.56M |
| Net income | -$62.15M | -$11.90M |
| EPS (basic) | -3.20 | -0.69 |
| EPS (diluted) | -3.20 | -0.69 |
| Weighted avg. shares (diluted) | 19.40M | 17.34M |
| Balance sheet | ||
| Cash & equivalents | $58,729 | $64,893 |
| Current assets | $1.39M | $2.20M |
| Intangibles | $500,000 | — |
| Total assets | $2.82M | $3.42M |
| Current liabilities | $20.04M | $8.92M |
| Total liabilities | $20.33M | $8.92M |
| Shareholders' equity | -$17.51M | -$5.50M |
| Shares outstanding | 21.99M | 18.09M |
| Cash flow statement | ||
| Operating cash flow | -$20.36M | -$4.21M |
| Capital expenditure | $500,000 | — |
| Free cash flow | -$20.86M | — |
| Investing cash flow | -$500,000 | — |
| Financing cash flow | $20.86M | $4.25M |
| Stock-based compensation | $35.56M | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.